National Institute for Health and Care Excellence2d
Published: Guidance, quality standards and advice
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments TA1023 11 December 2024 11 December 2024 ...
National Institute for Health and Care Excellence2d
Avatrombopag for treating primary chronic immune thrombocytopenia in people 1 to 17 years [TSID 12109]
Further information The NICE-Wide Prioritisation Board and NHS England have agreed that a Technology Appraisal (TA) would not be appropriate for this product and recommended that it is not selected ...
National Institute for Health and Care Excellence2d
Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
National Institute for Health and Care Excellence3d
NICE Health Technology Assessment training programme
have completed their Master of Public health (MPH) or individuals undertaking the portfolio route must have either passed their DFPH (Faculty of Public Health Diplomate Examination, formally Part A ...